Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer
| Autor: | Alex K. Bryant, Arno J. Mundt, James D. Murphy, Rana R. McKay, A. Karim Kader, John P. Einck, Brent S. Rose, Christopher J. Kane, J. Kellogg Parsons |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Biochemical recurrence
Cancer Research medicine.medical_specialty Radiation business.industry Urology Testosterone (patch) medicine.disease 030218 nuclear medicine & medical imaging Metastasis Androgen deprivation therapy 03 medical and health sciences Prostate cancer 0302 clinical medicine Oncology 030220 oncology & carcinogenesis medicine Radiology Nuclear Medicine and imaging Orchiectomy business Nadir (topography) Hormone |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 103:1068-1076 |
| ISSN: | 0360-3016 |
| Popis: | Purpose It is unclear if additional serum testosterone suppression below the castrate threshold of 50 ng/dL improves clinical outcomes in patients with localized prostate cancer undergoing definitive therapy. Methods and Materials We examined the association of subcastrate testosterone nadir with prostate-specific antigen (PSA) response and long-term clinical outcomes in 764 U.S. veterans with intermediate- or high-risk localized prostate cancer treated with androgen deprivation therapy and definitive radiation therapy from 2000 to 2015. Patients were categorized into testosterone nadir groups based on the minimum testosterone measurement during continuous gonadotropic-releasing hormone agonist therapy ( Results A testosterone nadir of 20 to 49 ng/dL was associated with higher 3-month post-radiation therapy PSA compared to Conclusions Additional serum testosterone suppression below 50 ng/dL was associated with improved PSA responses and lower rates of biochemical recurrence and metastasis in this cohort of patients with localized prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|